<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Canella R</submitter><funding>F. Brugnoli by FIRD2022</funding><funding>N. Bianchi by FAR2021</funding><funding>V. Bertagnolo by FAR2021</funding><funding>N. Bianchi by FIR2021</funding><funding>R. Canella by FAR2020</funding><funding>S. Volinia by FAR2021</funding><pagination>178</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9818547</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Since the multifunctionality of transglutaminase 2 (TG2) includes extra- and intracellular functions, we investigated the effects of intracellular administration of TG2 inhibitors in three breast cancer cell lines, MDA-MB-231, MDA-MB-436 and MDA-MB-468, which are representative of different triple-negative phenotypes, using a patch-clamp technique. The first cell line has a highly voltage-dependent a membrane current, which is low in the second and almost absent in the third one. While applying a voltage protocol to responsive single cells, injection of TG2 inhibitors triggered a significant decrease of the current in MDA-MB-231 that we attributed to voltage-dependent K&lt;sup>+&lt;/sup> channels using the specific inhibitors 4-aminopyridine and astemizole. Since the Kv10.1 channel plays a domin</pubmed_abstract><journal>Cancers</journal><pubmed_title>A Multidisciplinary Approach Establishes a Link between Transglutaminase 2 and the Kv10.1 Voltage-Dependent K&lt;sup>+&lt;/sup> Channel in Breast Cancer.</pubmed_title><pmcid>PMC9818547</pmcid><funding_grant_id>FAR2191074</funding_grant_id><funding_grant_id>FIR2191318</funding_grant_id><pubmed_authors>Bertagnolo V</pubmed_authors><pubmed_authors>Brugnoli F</pubmed_authors><pubmed_authors>Bergamini CM</pubmed_authors><pubmed_authors>Ferrari E</pubmed_authors><pubmed_authors>Gallo M</pubmed_authors><pubmed_authors>Keillor JW</pubmed_authors><pubmed_authors>Canella R</pubmed_authors><pubmed_authors>Terrazzan A</pubmed_authors><pubmed_authors>Bianchi N</pubmed_authors><pubmed_authors>Grassilli S</pubmed_authors><pubmed_authors>Gates EWJ</pubmed_authors><pubmed_authors>Volinia S</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Multidisciplinary Approach Establishes a Link between Transglutaminase 2 and the Kv10.1 Voltage-Dependent K&lt;sup>+&lt;/sup> Channel in Breast Cancer.</name><description>Since the multifunctionality of transglutaminase 2 (TG2) includes extra- and intracellular functions, we investigated the effects of intracellular administration of TG2 inhibitors in three breast cancer cell lines, MDA-MB-231, MDA-MB-436 and MDA-MB-468, which are representative of different triple-negative phenotypes, using a patch-clamp technique. The first cell line has a highly voltage-dependent a membrane current, which is low in the second and almost absent in the third one. While applying a voltage protocol to responsive single cells, injection of TG2 inhibitors triggered a significant decrease of the current in MDA-MB-231 that we attributed to voltage-dependent K&lt;sup>+&lt;/sup> channels using the specific inhibitors 4-aminopyridine and astemizole. Since the Kv10.1 channel plays a domin</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-04T20:33:12.045Z</modification><creation>2024-11-08T22:05:56.703Z</creation></dates><accession>S-EPMC9818547</accession><cross_references><pubmed>36612174</pubmed><doi>10.3390/cancers15010178</doi></cross_references></HashMap>